Effect of Rosa damascena on nonalcoholic fatty liver disease

Comparison of the effect of Rosa damascena with placebo on liver enzymes in patients with nonalcoholic fatty liver disease(NAFLD): a double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191006044994N1

Enrollment

Registered

2019-11-11

Start date

2019-11-19

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Alcoholic Fatty Liver Disease. Non Alcoholic Fatty Liver Disease

Interventions

Intervention 1: Intervention group: 500 mg capsules of Rosa damascena,6 capsules per day

each time 2 capsules(*3), Orally, For12 weeks. Intervention 2: Control group: Placebo (breadcrumbs), 500 mg capsule containing breadcrumbs, 6 capsules daily, three per day each time 2 capsules, orally

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Sonographic report of Grade 1- 2-3 fatty liver Increase in ALT> 38? Increase in AST>31 Ages 12 to 80 years Ages 18 to 80 years

Exclusion criteria

Exclusion criteria: The patient's unwillingness to participate in the scheme Pregnancy & lactation Anti coagulant drugs consumption Thyroid diseases Spleen diseases Cirrhosis ,viral hepatitis and obstructive liver disese Treated dyslipidemia Overt Diabetes mellitus Lung diseases Taking any medication that affects liver metabolism and enzymes, including oral contraceptives, corticosteroids, salazines, etc.

Design outcomes

Primary

Measure	Time frame
Alt(Alanin transaminase). Timepoint: Onset and 12th week of study(End of study). Method of measurement: Hitachi-912 biochemistery instrument.;Ast(Aspartate transaminase). Timepoint: Onset and 12th week of study(End of study). Method of measurement: Hitachi-912 biochemistery instrument.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Alihadi Moravej

Iran University of Medical Sciences

alimoravej713@gmail.com+98 21 7752 1303

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026